CCI Imposes Penalty of Rs. 18.38 Crores on Bengal Chemist and Druggist Association


New Delhi, March 15, 2014:
The Competition Commission of India (CCI) has imposed a penalty of Rs. 18.38 crores on Bengal Chemist and Druggist Association (BCDA) and its office bearers for anti-competitive practices. This has been done vide a common order in Suo moto Case No. 02 of 2012 and Reference Case No. 01 of 2013 filed by Dr. Chintamoni Ghosh, Director, Directorate of Drugs, West Bengal.

In the reference filed by Dr. Ghosh, it was alleged that BCDA is inter alia engaged in issuing anti-competitive circulars directing the retailers not to give any discount to the consumers. The CCI after considering the entire material had directed the Director General (DG) to cause an investigation into the matter and to submit a report.

The CCI observed that the activities of BCDA inter alia to direct its members to sell drugs only at their MRP is a palpable anti-competitive conduct which cannot be justified on the ground that most of the members of the BCDA, would be ruined if competitive forces are allowed to operate in the market. The CCI accordingly concluded that the activities of the BCDA are in conflict with the objects of the competition law as they cause restraint of trade, stifle competition and harm the consumers.

Holding that BCDA and its District and Zonal Committees were engaged in anti-competitive practices of directly or indirectly determining the sale prices of drugs and controlling or limiting the supply of drugs through concerted and restrictive practices, the CCI directed the BCDA and its office bearers and executive committee members to seize and desist from indulging in practices found to be anticompetitive in terms of the provisions of the Act.

After giving due consideration on the issue, the CCI decided to impose a penalty on the BCDA and its those office bearers who were directly responsible for running its affairs and play lead role in decision making @10% and on the executive committee members @7%, of their respective turnover/income/receipts.

The BCDA has been further directed to file an undertaking within 30 days that the CCI’s directions regarding seize and desist from indulging in anticompetitive practices have been complied with. The amount of penalty imposed was directed to be deposited within 60 of the receipt of the order. A copy of the order is available on the website of CCI (www.cci.gov.in). CCI Newswire

The Pharma Times News Bureau

Share
Published by
The Pharma Times News Bureau

Recent Posts

DKMS-BMST – Bridging the Care Gap in Blood Cancer Treatment on National Cancer Awareness Day

New Delhi, November 07, 2024: National Cancer Awareness Day serves as a poignant reminder of…

17 hours ago

The Arya Vaidya Pharmacy (Coimbatore) Ltd. Strengthens Legacy with New Initiatives and Expanded Product Portfolio

Coimbatore, November 07, 2024: The Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic…

17 hours ago

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

1 day ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

1 day ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

3 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

3 days ago